Wuhan General Hospital
Wuhan, Hubei, 430070, China
NCT Number: NCT01877603
Irisin is a signaling protein that is released into the blood from skeletal muscle after proteolysis of the membrane protein FNDC5 . FNDC5, encoded by the Fndc5 gene. Irisin activity on subcutaneous white adipose tissue, both in culture and in vivo, stimulated UCP1 expression and induction of brown adipocytes in white adipose tissue depots, a process known as white fat ''browning''. Irisin increases total energy expenditure in animal models, and irisin expression in mice fed a high fat diet resulted in a significant improvement in glucose tolerance and a reduction in fasting insulin levels. Collectively, these data suggest that decreased serum irisin levels may be associated with the development of insulin resistance and Type 2 diabetes. Indeed, some studies showed that irisin levels were decreased in newly diagnosed Type 2 diabetes.
Endothelial dysfunction is an early physiological event in atherosclerosis. However, to date, no data are available on the relationship between circulating irisin and endothelial dysfunction in diabetes. Therefore, the investigators hypothesized that circulating irisin level is associated with endothelial dysfunction.
Looking for future studies?
Notify Me40 year–70 year
All sexes
Observational
Wuhan, Hubei, 430070, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 months
Wuhan General Hospital of Guangzhou Military Command
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07268976
Adipokine Response, Brain-derived Neurotrophic Factor (BDNF)
Bayburt, Merkez, Turkey (Türkiye)
View Trial DetailsNCT07191015
Exercise Intensity, Irisin
Aksaray, Center, Turkey (Türkiye)
View Trial DetailsNCT07146490
Cognitive Function, Exercise Training
Aksaray, Center, Turkey (Türkiye)
View Trial DetailsNCT04156113
Irisin, Polymorphism, Restriction Fragment Length
Izmir, Turkey (Türkiye)
View Trial Details